Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma ...Middle East

Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen NEW ORLEANS, Dec. 10, 2022 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™...

Hence then, the article about janssen presents first data from majestec 2 trial of tecvayli teclistamab cqyv in combination with darzalex faspro daratumumab and hyaluronidase fihj and lenalidomide in relapsed or refractory multiple myeloma was published today ( Saturday 10/12/2022 - 09:16 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma )

Also on site :

• Primary school teacher banned after drinking can of beer in classroom and eating mints after every sip
• Greenland warns of ‘red lines’ in talks with US
• Why is ‘Deuce Bigalow’ rooting for Viktor Orban in Hungary?